NO20056007L - Dobbel NK1/NK3 antagonister for behandling av schizofreni - Google Patents
Dobbel NK1/NK3 antagonister for behandling av schizofreniInfo
- Publication number
- NO20056007L NO20056007L NO20056007A NO20056007A NO20056007L NO 20056007 L NO20056007 L NO 20056007L NO 20056007 A NO20056007 A NO 20056007A NO 20056007 A NO20056007 A NO 20056007A NO 20056007 L NO20056007 L NO 20056007L
- Authority
- NO
- Norway
- Prior art keywords
- schizophrenia
- treatment
- antagonists
- double
- medicaments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/547—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D419/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
Abstract
Anvendelse av forbindelser med den generelle formel hvor substituentene er ifølge krav 1 eller farmasøytisk aktive syre-addisjonssalter derav for fremstilling av medikamenter for behandling av schizofreni.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03014513 | 2003-07-03 | ||
PCT/EP2004/006929 WO2005002577A1 (en) | 2003-07-03 | 2004-06-25 | Dual nk1/nk3 antagonists for treating schizophrenia |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20056007L true NO20056007L (no) | 2006-01-19 |
Family
ID=33560750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20056007A NO20056007L (no) | 2003-07-03 | 2005-12-16 | Dobbel NK1/NK3 antagonister for behandling av schizofreni |
Country Status (27)
Country | Link |
---|---|
US (3) | US20050090533A1 (no) |
EP (1) | EP1643998B1 (no) |
JP (1) | JP4490421B2 (no) |
KR (1) | KR100744859B1 (no) |
CN (1) | CN1852712B (no) |
AR (1) | AR044974A1 (no) |
AT (1) | ATE371451T1 (no) |
AU (1) | AU2004253267B2 (no) |
BR (1) | BRPI0412291A (no) |
CA (1) | CA2530886C (no) |
CO (1) | CO5650234A2 (no) |
DE (1) | DE602004008631T2 (no) |
DK (1) | DK1643998T3 (no) |
ES (1) | ES2291891T3 (no) |
HR (1) | HRP20070471T3 (no) |
IL (1) | IL172614A (no) |
MX (1) | MXPA06000192A (no) |
MY (1) | MY137156A (no) |
NO (1) | NO20056007L (no) |
NZ (1) | NZ544244A (no) |
PL (1) | PL1643998T3 (no) |
PT (1) | PT1643998E (no) |
RU (1) | RU2347777C2 (no) |
SI (1) | SI1643998T1 (no) |
TW (1) | TW200502230A (no) |
WO (1) | WO2005002577A1 (no) |
ZA (1) | ZA200510453B (no) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004034619A1 (de) * | 2004-07-16 | 2006-02-23 | Grünenthal GmbH | Substituierte Aminoverbindungen als 5-HT/NA Uptakehemmer |
US20060030600A1 (en) * | 2004-08-06 | 2006-02-09 | Patrick Schnider | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia |
DE102004039789A1 (de) | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
NZ560448A (en) | 2005-02-16 | 2009-08-28 | Anacor Pharmaceuticals Inc | Boron-containing small molecules |
US7176205B2 (en) * | 2005-02-22 | 2007-02-13 | Hoffmann-La Roche Inc. | Bi-pyridinyl derivatives as NK-1 antagonists |
CA2602445C (en) * | 2005-03-23 | 2013-08-20 | F.Hoffmann-La Roche Ag | Metabolites for nk-i antagonists for emesis |
JP2008540438A (ja) * | 2005-05-04 | 2008-11-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルのモジュレーターとして有用なピリジン |
WO2006130493A2 (en) * | 2005-05-31 | 2006-12-07 | Vertex Pharmaceuticals Incorporated | Heterocycles useful as modulators of ion channels |
GB0518472D0 (en) * | 2005-09-09 | 2005-10-19 | Glaxo Group Ltd | Novel compounds |
AU2006289281B2 (en) | 2005-09-09 | 2012-05-17 | KaNDy Therapeutics Ltd. | Pyridine derivatives and their use in the treatment of psychotic disorders |
WO2007039123A2 (en) * | 2005-09-22 | 2007-04-12 | Smithkline Beecham Corporation | Combination therapy comprising an nk-3 antagonist and an antipsychotic agent |
CN102532180B (zh) * | 2005-12-30 | 2016-06-29 | 安纳考尔医药公司 | 含硼的小分子 |
RU2008131324A (ru) | 2005-12-30 | 2010-02-10 | Анакор Фармасьютикалз, Инк. (Us) | Борсодержащие малые молекулы |
EP2007726B1 (en) | 2006-02-07 | 2011-03-02 | F. Hoffmann-La Roche AG | Benzamide and heteroarene derivatives as cetp inhibitors |
MX2009011051A (es) * | 2007-04-20 | 2009-10-30 | Hoffmann La Roche | Derivados de pirrolidina como antagonistas del receptor nk1/nk3 doble. |
JP2010535733A (ja) | 2007-08-07 | 2010-11-25 | エフ.ホフマン−ラ ロシュ アーゲー | Nk3受容体アンタゴニストとしてのピロリジンアリールエーテル |
GB0808747D0 (en) * | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
GB0814340D0 (en) | 2008-08-05 | 2008-09-10 | Smithkline Beecham Corp | Anhydrous crystol form fo a pyridine derivative |
CN102639536B (zh) * | 2009-08-27 | 2015-03-18 | 尼尔医疗有限公司 | 吡啶衍生物的无水晶型 |
WO2011054773A1 (en) | 2009-11-03 | 2011-05-12 | Glaxosmithkline Llc | Novel lactam compounds |
US20110144081A1 (en) * | 2009-12-15 | 2011-06-16 | Henner Knust | Pyrrolidine derivatives |
US8487102B2 (en) * | 2010-04-20 | 2013-07-16 | Hoffmann-La Roche Inc. | Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists |
US8987307B2 (en) | 2011-03-03 | 2015-03-24 | Hoffmann-La Roche Inc. | 3-amino-pyridines as GPBAR1 agonists |
CA2930008A1 (en) * | 2013-11-08 | 2015-05-14 | Kissei Pharmaceutical Co., Ltd. | Carboxymethyl piperidine derivative |
TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
MX2017012720A (es) | 2015-05-18 | 2018-02-09 | Nerre Therapeutics Ltd | Antagonistas duales de receptores de neurocinina-1 (nk-1) / neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales. |
EA201992215A1 (ru) | 2017-03-20 | 2020-02-06 | Форма Терапьютикс, Инк. | Пирролопирроловые композиции в качестве активаторов пируваткиназы (pkr) |
KR20200139138A (ko) | 2018-03-14 | 2020-12-11 | 칸디 테라퓨틱스 리미티드 | 이중 nk-1/nk-3 수용체 길항제를 포함하는 신규한 제약 제제 |
EP3852791A4 (en) | 2018-09-19 | 2022-06-15 | Forma Therapeutics, Inc. | ACTIVATION OF PYRUVATE KINASE R |
US20220031671A1 (en) | 2018-09-19 | 2022-02-03 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
US20230002322A1 (en) | 2019-11-15 | 2023-01-05 | KaNDy Therapeutics Limited | New chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of nt-814 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
PL181214B1 (pl) | 1993-12-29 | 2001-06-29 | Merck Sharp & Dohme | Podstawione związki morfolinowe, sposób ich wytwarzania oraz zawierające je kompozycje farmaceutyczne |
IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
FR2719311B1 (fr) * | 1994-03-18 | 1998-06-26 | Sanofi Sa | Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic. |
CA2273807A1 (en) * | 1996-12-02 | 1998-06-11 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating schizophrenic disorders |
US5972938A (en) * | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
ES2226622T3 (es) * | 1999-02-24 | 2005-04-01 | F. Hoffmann-La Roche Ag | Derivados de 4-fenil piridina y su empleo como antagonistas del receptor nk-1. |
JP4070957B2 (ja) | 1999-02-24 | 2008-04-02 | エフ.ホフマン−ラ ロシュ アーゲー | フェニルおよびピリジニル誘導体 |
TR200302077T4 (tr) | 1999-11-29 | 2004-01-21 | F. Hoffmann-La Roche Ag | 2-(3,5-Bis-Trifluorometil-fenil)-N-metil-N- (6-morfonil-4-il-4-O-tolil-piridin-3-il)- izobütiramit |
CZ303639B6 (cs) * | 2000-07-14 | 2013-01-23 | F. Hoffmann-La Roche Ag | N-Oxid derivátu 4-fenylpyridinu, zpusob jeho prípravy a lécivo s jeho obsahem |
TWI287003B (en) * | 2000-07-24 | 2007-09-21 | Hoffmann La Roche | 4-phenyl-pyridine derivatives |
TWI259180B (en) * | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
EP1192952A3 (en) | 2000-09-28 | 2003-03-26 | Pfizer Products Inc. | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist |
AU2002250876B2 (en) * | 2001-04-23 | 2005-03-03 | F. Hoffmann-La Roche Ag | Use of NK-1 receptor antagonists against benign prostatic hyperplasia |
US20030083345A1 (en) * | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
-
2004
- 2004-06-25 PT PT04740337T patent/PT1643998E/pt unknown
- 2004-06-25 CN CN2004800253601A patent/CN1852712B/zh not_active Expired - Fee Related
- 2004-06-25 EP EP04740337A patent/EP1643998B1/en active Active
- 2004-06-25 SI SI200430471T patent/SI1643998T1/sl unknown
- 2004-06-25 WO PCT/EP2004/006929 patent/WO2005002577A1/en active IP Right Grant
- 2004-06-25 CA CA2530886A patent/CA2530886C/en not_active Expired - Fee Related
- 2004-06-25 JP JP2006518043A patent/JP4490421B2/ja not_active Expired - Fee Related
- 2004-06-25 AU AU2004253267A patent/AU2004253267B2/en not_active Ceased
- 2004-06-25 DK DK04740337T patent/DK1643998T3/da active
- 2004-06-25 KR KR1020067000167A patent/KR100744859B1/ko not_active IP Right Cessation
- 2004-06-25 NZ NZ544244A patent/NZ544244A/xx unknown
- 2004-06-25 PL PL04740337T patent/PL1643998T3/pl unknown
- 2004-06-25 ES ES04740337T patent/ES2291891T3/es active Active
- 2004-06-25 MX MXPA06000192A patent/MXPA06000192A/es active IP Right Grant
- 2004-06-25 BR BRPI0412291-7A patent/BRPI0412291A/pt not_active Application Discontinuation
- 2004-06-25 AT AT04740337T patent/ATE371451T1/de active
- 2004-06-25 DE DE602004008631T patent/DE602004008631T2/de active Active
- 2004-06-25 RU RU2006103010/04A patent/RU2347777C2/ru not_active IP Right Cessation
- 2004-06-30 TW TW093119675A patent/TW200502230A/zh unknown
- 2004-07-01 AR ARP040102313A patent/AR044974A1/es not_active Application Discontinuation
- 2004-07-02 US US10/884,707 patent/US20050090533A1/en not_active Abandoned
- 2004-07-02 MY MYPI20042647A patent/MY137156A/en unknown
-
2005
- 2005-12-15 IL IL172614A patent/IL172614A/en not_active IP Right Cessation
- 2005-12-16 NO NO20056007A patent/NO20056007L/no not_active Application Discontinuation
- 2005-12-22 ZA ZA200510453A patent/ZA200510453B/en unknown
- 2005-12-29 CO CO05131296A patent/CO5650234A2/es not_active Application Discontinuation
-
2007
- 2007-10-10 HR HR20070471T patent/HRP20070471T3/xx unknown
-
2009
- 2009-01-29 US US12/361,569 patent/US7939533B2/en not_active Expired - Fee Related
-
2011
- 2011-03-31 US US13/076,891 patent/US8404708B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20056007L (no) | Dobbel NK1/NK3 antagonister for behandling av schizofreni | |
AP1635A (en) | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease. | |
IS8503A (is) | Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar | |
SE0104334D0 (sv) | Therapeutic agents | |
DE60315674D1 (de) | Neue imidazopyridine und ihre verwendung | |
CY1107853T1 (el) | Χρησεις αντισπασμωδικων αμινοξεων για τη θεραπευτικη αγωγη διπολικων διαταραχων | |
BG106825A (en) | Substituted oxazolidinones and their use in the field of blood coagulation | |
IS8502A (is) | Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar | |
EA200500342A1 (ru) | Гетероциклические замещённые пиперазины для лечения шизофрении | |
NO331174B1 (no) | Substituerte 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazinderivater og deres anvendelse som neurokininantagonister | |
NO20060147L (no) | Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav | |
DE60045508D1 (de) | Dalda-analoge und ihre verwendung | |
NO20060146L (no) | Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav | |
DE60305514D1 (de) | Neue verwendung von benzothiazolderivaten | |
BG108498A (en) | New derivatives of oxazolidinones as antibacterial agents | |
EE200000527A (et) | Faktorit Xa pärssivad heterotsüklilised derivaadid | |
ATE186301T1 (de) | An den positionen 2 und 9 substituierte 4h-pyrido-(1,2-a)pyrimidin-4-one | |
WO2007125398A3 (en) | : sulfonamide compounds as antagonists of the n-type calcium channel | |
ATE444069T1 (de) | Chinolin-derivate zur behandlung von mglur5- rezeptor-vermittelten erkrankungen | |
MXPA05005790A (es) | Aminoalcoxiindoles como ligandos del receptor 5-ht6 para el tratamiento de enfermedades del sistema nervioso central. | |
DE69923444D1 (de) | Heterozyklische verbindungen mit faktor xa hemmender wirkung | |
TW200833697A (en) | Spiro-piperidine derivatives | |
HRP20050831A2 (en) | Novel oxazole derivatives, their manufacture and use as pharmaceutical agents | |
BR0110255A (pt) | Cromenilmetil pirimidinadiaminas como agentes antibacterianos | |
JP2007507467A5 (no) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |